Kerry A Thomson1, Jared M Baeten, Nelly R Mugo, Linda-Gail Bekker, Connie L Celum, Renee Heffron. 1. aDepartment of Global Health bDepartment of Epidemiology cDepartment of Medicine, University of Washington, Seattle, USA dSexual Reproductive Adolescent and Child Health Program, Kenya Medical Research Institute, Nairobi, Kenya eThe Desmond Tutu HIV Centre, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Abstract
PURPOSE OF REVIEW: Despite tremendous promise as a female-controlled HIV prevention strategy, implementation of preexposure prophylaxis (PrEP) among women has been limited, in part because of disparate efficacy results from randomized trials in this population. This review synthesizes existing evidence regarding PrEP efficacy for preventing HIV infection in women and considerations for delivering PrEP to women. RECENT FINDINGS: In three efficacy trials, conducted among men and women, tenofovir-based oral PrEP reduced HIV acquisition in subgroups of women by 49-79% in intent-to-treat analyses, and by >85% when accounting for PrEP adherence. Two trials did not demonstrate an HIV prevention benefit from PrEP in women, but substantial evidence indicates those results were compromised by very low adherence to the study medication. Qualitative research has identified risk perception, stigma, and aspects of clinical trial participation as influencing adherence to study medication. Pharmacokinetic studies provide supporting evidence that PrEP offers HIV protection in women who are adherent to the medication. SUMMARY: Tenofovir-based daily oral PrEP prevents HIV acquisition in women. Offering PrEP as an HIV prevention option for women at high risk of HIV acquisition is a public health imperative and opportunities to evaluate implementation strategies for PrEP for women are needed.
PURPOSE OF REVIEW: Despite tremendous promise as a female-controlled HIV prevention strategy, implementation of preexposure prophylaxis (PrEP) among women has been limited, in part because of disparate efficacy results from randomized trials in this population. This review synthesizes existing evidence regarding PrEP efficacy for preventing HIV infection in women and considerations for delivering PrEP to women. RECENT FINDINGS: In three efficacy trials, conducted among men and women, tenofovir-based oral PrEP reduced HIV acquisition in subgroups of women by 49-79% in intent-to-treat analyses, and by >85% when accounting for PrEP adherence. Two trials did not demonstrate an HIV prevention benefit from PrEP in women, but substantial evidence indicates those results were compromised by very low adherence to the study medication. Qualitative research has identified risk perception, stigma, and aspects of clinical trial participation as influencing adherence to study medication. Pharmacokinetic studies provide supporting evidence that PrEP offers HIV protection in women who are adherent to the medication. SUMMARY:Tenofovir-based daily oral PrEP prevents HIV acquisition in women. Offering PrEP as an HIV prevention option for women at high risk of HIV acquisition is a public health imperative and opportunities to evaluate implementation strategies for PrEP for women are needed.
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Holly Janes; Lawrence Corey; Gita Ramjee; Lindsay N Carpp; Carl Lombard; Myron S Cohen; Peter B Gilbert; Glenda E Gray Journal: AIDS Res Hum Retroviruses Date: 2018-06-19 Impact factor: 2.205
Authors: Angela R Bazzi; Ashley A Leech; Dea L Biancarelli; Meg Sullivan; Mari-Lynn Drainoni Journal: AIDS Patient Care STDS Date: 2017-07-18 Impact factor: 5.078
Authors: Wayne T Steward; Veena A Satyanarayana; Elsa Heylen; Aylur K Srikrishnan; Canjeevaram K Vasudevan; Gopal Krishnan; Davidson Solomon; Maria L Ekstrand Journal: AIDS Care Date: 2017-10-30
Authors: Catherine A Koss; Albert Y Liu; Jose Castillo-Mancilla; Peter Bacchetti; Cricket McHugh; Karen Kuncze; Mary Morrow; Alexander Louie; Sharon Seifert; Hideaki Okochi; Samantha MaWhinney; Monica Gandhi; Peter L Anderson Journal: AIDS Date: 2018-09-24 Impact factor: 4.177
Authors: Jared M Baeten; Thesla Palanee-Phillips; Elizabeth R Brown; Katie Schwartz; Lydia E Soto-Torres; Vaneshree Govender; Nyaradzo M Mgodi; Flavia Matovu Kiweewa; Gonasagrie Nair; Felix Mhlanga; Samantha Siva; Linda-Gail Bekker; Nitesha Jeenarain; Zakir Gaffoor; Francis Martinson; Bonus Makanani; Arendevi Pather; Logashvari Naidoo; Marla Husnik; Barbra A Richardson; Urvi M Parikh; John W Mellors; Mark A Marzinke; Craig W Hendrix; Ariane van der Straten; Gita Ramjee; Zvavahera M Chirenje; Clemensia Nakabiito; Taha E Taha; Judith Jones; Ashley Mayo; Rachel Scheckter; Jennifer Berthiaume; Edward Livant; Cindy Jacobson; Patrick Ndase; Rhonda White; Karen Patterson; Donna Germuga; Beth Galaska; Katherine Bunge; Devika Singh; Daniel W Szydlo; Elizabeth T Montgomery; Barbara S Mensch; Kristine Torjesen; Cynthia I Grossman; Nahida Chakhtoura; Annalene Nel; Zeda Rosenberg; Ian McGowan; Sharon Hillier Journal: N Engl J Med Date: 2016-02-22 Impact factor: 91.245
Authors: Ashley L Buchanan; S Bessey; William C Goedel; Maximilian King; Eleanor J Murray; Samuel R Friedman; M Elizabeth Halloran; Brandon D L Marshall Journal: Am J Epidemiol Date: 2021-05-04 Impact factor: 4.897
Authors: D Kerrigan; A Mantsios; R Grant; M Markowitz; P Defechereux; M La Mar; S W Beckham; P Hammond; D Margolis; M Murray Journal: AIDS Behav Date: 2018-11